dolutegravir/lamivudine vs rifampin
According to this portal's Publishing Organization, this page was last reviewed in August 2026 against our methodology. Figures and extracts on this site, including tables above 1,000 rows when the corpus is that large, are the publisher's responsibility.
Side-by-side comparison of dolutegravir/lamivudine and rifampin. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
minor Known Drug Interaction
Antimycobacterial: Rifampin a ↓Dolutegravir An additional 50-mg dose of dolutegravir should be taken, separated by 12 hours from DOVATO [see Dosage and Administration ( 2.3 )] .
Dovato
Rifadin
Dovato is a complete HIV-1 treatment that combines two medicines into one tablet. It is used for adults and adolescents who weigh at least 55 pounds.
Rifampin is an antibiotic medicine. It fights bacteria in your body to treat infections.
Dovato is used to treat HIV-1 infection in adults and adolescents (12 years and older, weighing at least 55 pounds). It can be used if you have never taken HIV-1 medicines before. It can also be used to replace your current HIV-1 medicines if your virus is under control (HIV-1 RNA less than 50 copies/mL) and you have not had treatment failure or resistance to the medicines in Dovato.
Rifampin treats tuberculosis (TB) and helps eliminate the bacteria that cause meningitis from your nose and throat. It is important to use rifampin only for infections that are proven or strongly suspected to be caused by bacteria. This helps to prevent bacteria from becoming resistant to the medicine.
Dovato contains two drugs: dolutegravir and lamivudine. Dolutegravir blocks HIV-1 integrase, an enzyme the virus needs to multiply. Lamivudine blocks reverse transcriptase, another enzyme HIV-1 needs to make copies of itself.
Rifampin works by stopping bacteria from growing and multiplying. It does this by blocking a key enzyme that the bacteria need to make proteins. This helps your body fight off the infection.
- • Headache
- • Nausea
- • Diarrhea
- • Trouble sleeping (insomnia)
- • Tiredness (fatigue)
- • Heartburn
- • Upset stomach
- • Loss of appetite
- • Nausea
- • Vomiting
- Pain 1,425
- Anxiety 1,051
- Emotional Distress 1,048
- Anhedonia 942
- Chronic Kidney Disease 701
- Drug Interaction 970
- Drug Reaction With Eosinophilia And Systemic Symptoms 727
- Nausea 628
- Condition Aggravated 550
- Pyrexia 541
If you have both HIV-1 and hepatitis B, you should be tested for hepatitis B before starting Dovato. Using Dovato can cause the hepatitis B virus to become resistant to lamivudine. Stopping Dovato can also cause a severe worsening of hepatitis B. Your liver function should be checked regularly.
Rifampin can cause liver problems. Tell your doctor right away if you have yellowing of the skin or eyes, dark urine, or stomach pain. Rifampin can also cause blood problems. Tell your doctor if you have unusual bleeding or bruising.
There is a pregnancy registry to monitor outcomes in people exposed to Dovato during pregnancy. Talk to your doctor if you are pregnant or plan to become pregnant. There may be a risk of neural tube defects if dolutegravir is taken at the time of conception.
Tell your doctor if you are pregnant or plan to become pregnant. Rifampin can make birth control pills less effective, so use other forms of birth control. Talk to your doctor if you are breastfeeding.
Also Compare, Nearby Drugs
Compare dolutegravir/lamivudine with
How to Read This dolutegravir/lamivudine vs rifampin Comparison
dolutegravir/lamivudine is classified in the Integrase Inhibitor / NRTI Combination drug class, while rifampin sits within the Rifamycin Antibiotic class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, dolutegravir/lamivudine has 5,167 submissions while rifampin has 3,416. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known minor interaction flagged in FDA labeling, attributed to rifampin makes your body process dolutegravir too quickly, leading to lower levels of the medication in your body.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for dolutegravir/lamivudine or rifampin.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.